Merck Gains Early-Stage Protease Inhibitor For HIV/AIDS Through Ambrilia Deal
This article was originally published in The Pink Sheet Daily
Licensing agreement includes rights to Ambrilia's lead compound PPL-100 in Phase I development as a once-daily, first-line oral therapy for HIV.
You may also be interested in...
The Canadian company will pair with Teva in Europe on its formulation of Novartis’ acromegaly therapy Sandostatin LAR.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.